PAVmed (PAVM) Competitors $0.59 +0.01 (+0.85%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$0.60 +0.01 (+0.84%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PAVM vs. NEPH, MODD, PYPD, POCI, COCH, VVOS, DRIO, FEMY, CLGN, and ALURShould you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Nephros (NEPH), Modular Medical (MODD), PolyPid (PYPD), Precision Optics (POCI), Envoy Medical (COCH), Vivos Therapeutics (VVOS), DarioHealth (DRIO), Femasys (FEMY), CollPlant Biotechnologies (CLGN), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry. PAVmed vs. Its Competitors Nephros Modular Medical PolyPid Precision Optics Envoy Medical Vivos Therapeutics DarioHealth Femasys CollPlant Biotechnologies Allurion Technologies PAVmed (NASDAQ:PAVM) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Which has stronger earnings and valuation, PAVM or NEPH? PAVmed has higher earnings, but lower revenue than Nephros. PAVmed is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPAVmed$2.99M3.39$39.79M$0.710.84Nephros$14.16M2.64$70K$0.0750.43 Does the media favor PAVM or NEPH? In the previous week, PAVmed's average media sentiment score of 0.00 equaled Nephros'average media sentiment score. Company Overall Sentiment PAVmed Neutral Nephros Neutral Do institutionals and insiders believe in PAVM or NEPH? 19.9% of PAVmed shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 7.3% of PAVmed shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, PAVM or NEPH? PAVmed has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Do analysts recommend PAVM or NEPH? PAVmed currently has a consensus target price of $19.00, indicating a potential upside of 3,104.05%. Nephros has a consensus target price of $5.00, indicating a potential upside of 41.64%. Given PAVmed's higher possible upside, analysts plainly believe PAVmed is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PAVM or NEPH more profitable? PAVmed has a net margin of 3,711.54% compared to Nephros' net margin of 5.16%. Nephros' return on equity of 9.43% beat PAVmed's return on equity.Company Net Margins Return on Equity Return on Assets PAVmed3,711.54% N/A -42.29% Nephros 5.16%9.43%7.20% SummaryPAVmed and Nephros tied by winning 6 of the 12 factors compared between the two stocks. Get PAVmed News Delivered to You Automatically Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAVM vs. The Competition Export to ExcelMetricPAVmedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.05M$6.68B$5.57B$9.42BDividend YieldN/A1.30%4.05%3.99%P/E Ratio0.8425.4528.1520.08Price / Sales3.3964.05401.6884.07Price / CashN/A20.2736.1958.45Price / Book-0.644.798.625.83Net Income$39.79M$176.14M$3.24B$258.27M7 Day Performance-1.17%2.47%3.55%2.69%1 Month Performance-2.39%4.42%11.01%12.91%1 Year Performance-42.98%7.42%35.56%21.81% PAVmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAVMPAVmed3.4845 of 5 stars$0.59+0.9%$19.00+3,104.0%-44.6%$10.05M$2.99M0.8490NEPHNephros2.3495 of 5 stars$3.57-1.9%$5.00+40.1%+61.2%$38.64M$14.16M51.0130MODDModular Medical0.2984 of 5 stars$0.70+1.3%N/A-55.3%$37.45MN/A-1.3720PYPDPolyPid2.35 of 5 stars$3.75+3.6%$11.80+214.7%+7.1%$36.89MN/A-0.8780POCIPrecision Optics0.1693 of 5 stars$4.81+1.1%N/A-23.2%$36.49M$19.10M-5.4080Gap UpCOCHEnvoy Medical2.2114 of 5 stars$1.61flat$9.25+474.5%-29.8%$34.34M$220K-1.1734VVOSVivos Therapeutics0.8491 of 5 stars$5.44-6.5%$4.82-11.5%+131.8%$34.28M$15.03M-3.14160DRIODarioHealth1.388 of 5 stars$0.70+2.8%$2.00+183.7%-42.6%$30.50M$27.04M-1.26200FEMYFemasys2.5015 of 5 stars$0.88-0.2%$8.67+882.6%-21.0%$28.75M$1.63M-0.9730CLGNCollPlant Biotechnologies1.8753 of 5 stars$2.24+10.3%$11.50+413.4%-50.3%$25.81M$510K-1.8470High Trading VolumeALURAllurion Technologies2.9763 of 5 stars$3.17+0.8%$22.83+621.4%-85.3%$23.42M$32.11M-0.25501 Related Companies and Tools Related Companies Nephros Competitors Modular Medical Competitors PolyPid Competitors Precision Optics Competitors Envoy Medical Competitors Vivos Therapeutics Competitors DarioHealth Competitors Femasys Competitors CollPlant Biotechnologies Competitors Allurion Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PAVM) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PAVM Stock Alerts